Nov 18, 2023, 19:38
Mark Awad: Our outstanding medical student Malini Gandhi shows that cancers with wild-type RET amplification can also be successfully targeted
Dr. Mark Awad, Associate Professor of Medicine at Harvard Medical School and Clinical Director of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, shared on X (Twitter):
“We know about targeting RET fusion+ lung cancer. Now out in JCO Precision Oncology, our outstanding medical student Malini Gandhi
shows that cancers with wild-type RET amplification can also be successfully targeted with selpercatinib.”
Full article here: Amplification of Wild-Type RET Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to Selpercatinib
Source: Mark Awad / X (Twitter)
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 11:52
Nov 13, 2024, 11:48
Nov 13, 2024, 11:44
Nov 13, 2024, 11:39
Nov 13, 2024, 11:30
Nov 13, 2024, 11:25
Nov 13, 2024, 11:10
Nov 13, 2024, 10:59
Nov 13, 2024, 10:54